REFERENCES
- Früs-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193.
- Früs-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
- Früs-Moller N, Reiss P, Sabin CA, et al. Class of antiret-roviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735.
- Murphy RL, Sanne I, Cahn P et al. Dose-ranging, ran-domized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603–2614.
- Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (A1424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavu-dine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18–29.
- Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combina-tion with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011–1019.
- Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684–692.
- Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipi-demia. J Acquir Immune Defic Syndr 2005;39:174–180.
- Martinez E, Azuaje C, Antela A, et al. Effects of switching to ritonavir-boosted atazanavir on HIV-infected patients receiv-ing antiretroviral therapy with hyperlipidemia. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22, 2005; Boston, MA.
- Sension M, Grinsztejn B, Molina J, et al. Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at base-line. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22, 2005; Boston, MA.
- Johnson M, Grinsztejn B, Rodriguez C, et al. Atazana-vir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685–694.
- Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral ther-apy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (A1424-097) 48-week results. Clin Infect Dis. 2007;44:1484–1492.
- Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother. 2008;61:200–205.
- Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.
- Gras L, van Sighem A, Smit C, Zaheri S, Schuitemaker H, de Wolf F. Monitoring of Human Immunodeficiency Virus (H10 Infection in the Netherlands. Amsterdam, The Netherlands: Stichting; 2007.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
- Fisac C, Fumero E, Crespo M, et al. Metabolic ben-efits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917–925.
- Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin. 2005;21:1683–1692.